uniQure N.V. logo
uniQure N.V. QURE
$ 22.43 -1.8%

Quarterly report 2025-Q3
added 11-10-2025

report update icon

uniQure N.V. Balance Sheet 2011-2026 | QURE

Annual Balance Sheet uniQure N.V.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-104 M -131 M -117 M -450 M -204 M -305 M -199 M -139 M -112 M -201 M -43.8 M -22.6 M 247 K -1.19 M

Long Term Debt

51.3 M 102 M 103 M 101 M 35.6 M 36.1 M 35.5 M 19.7 M 19.6 M 14.7 M 20 M 8.69 M - -

Long Term Debt Current

3.6 M 8.34 M 8.38 M 5.77 M 5.52 M 5.86 M - 1.05 M 605 K - - - - -

Total Non Current Liabilities

523 M 550 M 153 M 177 M 69.2 M 93.9 M 74.3 M 101 M 104 M 107 M 49.2 M 31.7 M 595 K 6.12 M

Total Current Liabilities

40.1 M 73.7 M 75.9 M 36.8 M 27.3 M 31.6 M 20 M 19.2 M 22.7 M - - - - -

Total Liabilities

563 M 624 M 229 M 213 M 96.5 M 126 M 94.3 M 120 M 127 M 134 M 64.1 M 46.1 M 7.95 M 10.9 M

Deferred Revenue

- - - - - 7.63 M 7.63 M 4.61 M 6.14 M 6.81 M 1.61 M 1.77 M - -

Retained Earnings

-1.13 B -890 M -582 M -455 M -785 M -660 M -536 M -475 M -396 M -276 M -220 M -199 M -155 M -137 M

Total Assets

557 M 832 M 705 M 809 M 340 M 449 M 274 M 210 M 190 M 265 M 116 M 53.8 M 7.36 M 7.52 M

Cash and Cash Equivalents

159 M 241 M 228 M 556 M 245 M 378 M 235 M 159 M 132 M 222 M - - - -

Book Value

-6.75 M 208 M 476 M 596 M 244 M 323 M 180 M 89.4 M 63.6 M 131 M 52.4 M 7.68 M -592 K -3.36 M

Total Shareholders Equity

-6.75 M 208 M 476 M 596 M 244 M 323 M 180 M 89.4 M 63.6 M 128 M 42.6 M - - -

All numbers in USD currency

Quarterly Balance Sheet uniQure N.V.

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

51.9 M 51.8 M 51.6 M 51.3 M 51.1 M 103 M 102 M 102 M 101 M 101 M 103 M 103 M 102 M 102 M 101 M 101 M 71.5 M 70.8 M 70.5 M 35.6 M 35.6 M 35.6 M 35.6 M 36.1 M 36.1 M 36.1 M 36.1 M 35.5 M 35.5 M 35.5 M 35.5 M 19.7 M 19.7 M 19.7 M 19.7 M 19.6 M 19.6 M 19.6 M 19.6 M 14.6 M - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

559 M 548 M 535 M 523 M 519 M 553 M 560 M 550 M 534 M 521 M 152 M 153 M 153 M 166 M 166 M 177 M 142 M 105 M 103 M 69.2 M 69.2 M 69.2 M 69.2 M 93.9 M 93.9 M 93.9 M 93.9 M 74.3 M 74.3 M 74.3 M 74.3 M 101 M 101 M 101 M 101 M 104 M 104 M 104 M 104 M 108 M - - - - - - - - - - - - - - - - - - -

Total Liabilities

660 M 589 M 572 M 563 M 590 M 634 M 623 M 624 M 603 M 589 M 218 M 229 M 217 M 215 M 211 M 213 M 184 M 151 M 135 M 96.5 M 96.5 M 96.5 M 96.5 M 126 M 126 M 126 M 126 M 94.3 M 94.3 M 94.3 M 94.3 M 120 M 120 M 120 M 120 M 127 M 127 M 127 M 127 M 135 M - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - 2.08 M 2.08 M 6.15 M 6.73 M 7.63 M 7.63 M 7.63 M 7.63 M 7.63 M 7.63 M 7.63 M 7.63 M 4.61 M 4.25 M 5.2 M 6.22 M 6.14 M 6.14 M 6.14 M 6.14 M 6.78 M - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.29 B -1.21 B -1.17 B -1.13 B -1.06 B -1.01 B -956 M -890 M -817 M -728 M -659 M -582 M -589 M -541 M -502 M -455 M -463 M -427 M -826 M -785 M -785 M -785 M -785 M -660 M -660 M -660 M -660 M -536 M -536 M -536 M -536 M -475 M -475 M -475 M -475 M -396 M -396 M -396 M -396 M -323 M - - - - - - - - - - - - - - - - - - -

Total Assets

888 M 585 M 605 M 557 M 646 M 731 M 770 M 832 M 872 M 943 M 631 M 705 M 638 M 701 M 757 M 809 M 775 M 784 M 364 M 340 M 340 M 340 M 340 M 449 M 449 M 449 M 449 M 274 M 274 M 274 M 274 M 210 M 210 M 210 M 210 M 190 M 190 M 190 M 190 M 263 M - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

597 M 254 M 217 M 159 M 252 M 288 M 243 M 241 M 229 M 514 M 154 M 228 M 440 M 501 M 525 M 556 M 578 M 677 M 261 M 248 M 245 M 245 M 245 M 378 M 378 M 378 M 378 M 235 M 235 M 235 M 235 M 159 M 159 M 159 M 159 M 132 M 132 M 132 M 132 M 222 M - - - 64.7 M - - - 32.8 M - - - - - - - - - - -

Book Value

229 M -4 M 33.7 M -6.75 M 55.8 M 97.1 M 147 M 208 M 269 M 353 M 413 M 476 M 421 M 486 M 546 M 596 M 591 M 634 M 229 M 244 M 244 M 244 M 244 M 323 M 323 M 323 M 323 M 180 M 180 M 180 M 180 M 89.4 M 89.4 M 89.4 M 89.4 M 63.6 M 63.6 M 63.6 M 63.6 M 128 M - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

229 M -4 M 33.7 M -6.75 M 55.8 M 97.1 M 147 M 208 M 269 M 353 M 413 M 476 M 421 M 486 M 546 M 596 M 591 M 634 M 229 M 244 M 244 M 244 M 244 M 323 M 323 M 323 M 323 M 180 M 180 M 180 M 180 M 89.4 M 89.4 M 89.4 M 89.4 M 63.6 M 63.6 M 63.6 M 63.6 M 128 M - - - 42.6 M - - - 2.29 M - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of uniQure N.V., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Adagene Adagene
ADAG
$ 1.9 -3.11 % $ 107 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.88 -0.73 % $ 1.25 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.31 -4.06 % $ 7.96 B australiaAustralia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.7 1.5 % $ 17 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.9 0.52 % $ 908 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
BioNTech SE BioNTech SE
BNTX
$ 106.07 -2.69 % $ 27.2 B germanyGermany
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.96 -1.0 % $ 8.62 B israelIsrael
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 0.95 -0.72 % $ 129 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 215.17 4.54 % $ 5 B danmarkDanmark
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.17 -1.89 % $ 1.62 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 64.51 1.04 % $ 8.63 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.24 2.38 % $ 2.75 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.65 -0.72 % $ 1.56 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.0 3.63 % $ 922 M usaUSA
Biogen Biogen
BIIB
$ 164.49 0.04 % $ 23.9 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
BioVie BioVie
BIVI
$ 1.24 2.49 % $ 1.83 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA